FDA OKs Two Gene-Editing Therapies for Sickle Cell Disease

The approval for the two gene-editing treatments, called exa-cel and lovo-cel, could help thousands with the blood disorder.

Related Keywords

United States ,American ,Roberta Brodsky ,Franco Locatelli ,Nicole Verdun ,Johns Hopkins University School Of Medicine ,Sapienza University Of Rome ,Vertex Pharmaceuticals ,Drug Administration ,American Society Of Hematology ,Crispr Therapeutics ,Johns Hopkins University School ,American Society ,Biologics Evaluation ,Sapienza University ,Genomics Genomic Medicine ,Sickle Cell Disease ,Ickle Cell Anemia Sickle Anaemia ,Blood ,Lysosomal Storage Disease ,Blood Transfusion ,I Cell Disease ,Ucolipidosis Type Ii ,Nclusion Cell Disease ,Ucolipidosis Ii ,Ol Ii ,Transplantation Of Stem Cells ,Ransplantation Of Hematopoietic Stem Cells ,Hematopoietic Stem Cell Transplant ,Stem Cell Transplantation ,Stem Cell Therapy ,